Specifically, HDAC3 and HDAC8 have been implicated in promoting insulin resistance and β‐catenin activation in MASLD‐associated HCC, while inhibition of HDAC2 and HDAC3 has been shown to ameliorate hepatic steatosis and inflammation in experimental models. Here, HDAC3 is linked to hepatocellular carcinoma.